A new trading day began on Tuesday, with Elevance Health Inc (NYSE: ELV) stock price up 0.55% from the previous day of trading, before settling in for the closing price of $370.89. ELV’s price has ranged from $362.21 to $567.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 13.24% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 0.12%. With a float of $231.44 million, this company’s outstanding shares have now reached $231.93 million.
In an organization with 104900 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 27.94%, operating margin of 5.29%, and the pretax margin is 4.77%.
Elevance Health Inc (ELV) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Healthcare Plans Industry. The insider ownership of Elevance Health Inc is 0.21%, while institutional ownership is 90.41%. The most recent insider transaction that took place on Oct 18 ’24, was worth 3,205,182. In this transaction EVP & President, Commercial of this company sold 7,417 shares at a rate of $432.14, taking the stock ownership to the 8,423 shares. Before that another transaction happened on Oct 18 ’24, when Company’s Director proposed sale 7,417 for $432.28, making the entire transaction worth $3,206,221.
Elevance Health Inc (ELV) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 0.12% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.01% during the next five years compared to 12.18% growth over the previous five years of trading.
Elevance Health Inc (NYSE: ELV) Trading Performance Indicators
Here are Elevance Health Inc’s current performance indicators. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.50. Likewise, its price to free cash flow for the trailing twelve months is 99.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 27.43, a number that is poised to hit 3.98 in the next quarter and is forecasted to reach 34.91 in one year’s time.
Technical Analysis of Elevance Health Inc (ELV)
Let’s dig in a bit further. During the last 5-days, its volume was 1.99 million. That was better than the volume of 1.25 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 26.53%. Additionally, its Average True Range was 9.64.
During the past 100 days, Elevance Health Inc’s (ELV) raw stochastic average was set at 5.23%, which indicates a significant decrease from 28.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.78% in the past 14 days, which was lower than the 27.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $406.28, while its 200-day Moving Average is $497.32. However, in the short run, Elevance Health Inc’s stock first resistance to watch stands at $374.90. Second resistance stands at $376.87. The third major resistance level sits at $380.45. If the price goes on to break the first support level at $369.35, it is likely to go to the next support level at $365.77. Assuming the price breaks the second support level, the third support level stands at $363.80.
Elevance Health Inc (NYSE: ELV) Key Stats
With a market capitalization of 86.49 billion, the company has a total of 231,923K Shares Outstanding. Currently, annual sales are 171,340 M while annual income is 5,987 M. The company’s previous quarter sales were 45,106 M while its latest quarter income was 1,016 M.
